Carlos Rodríguez-Nogales
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Carlos Rodríguez-Nogales has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- María J. Blanco-Prieto
University of Navarra
2 shared publications - Adela Cañete
Hospital Universitario y Politècnico La Fe, 46026 Valencia, Spain
1 shared publication - Carolina Zandueta
IdiSNA, Navarra Institute for Health Research, 31008 Pamplona, Spain
1 shared publication - Didier Desmaële
Université Paris-Saclay, UMR CNRS8612, Institut Galien Paris-Saclay, 17, Avenue des Sciences 91400, Orsay, France
1 shared publication - Fernando Lecanda
Division of Oncology, Solid Tumors Program, Center for Applied Medical Research (CIMA)-University of Navarra, Pamplona, Spain
1 shared publication - Haritz Moreno
Solid Tumors Program. Division of Oncology, Center for Applied Medical Research (CIMA)-University of Navarra, Pamplona, Spain
1 shared publication
Latest Publications
- 1 October 2021
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 608, 121058
Unraveling the extracellular matrix-tumor cell interactions to aid better targeted therapies for neuroblastoma
- 1 October 2021
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 608, 121058
Unraveling the extracellular matrix-tumor cell interactions to aid better targeted therapies for neuroblastoma
- Open Access
Combinatorial Nanomedicine Made of Squalenoyl-Gemcitabine and Edelfosine for the Treatment of Osteosarcoma
Due to chemoresistance and a high propensity to form lung metastasis, survival rates in pediatric osteosarcoma (OS) are poor. With the aim to improve anticancer activity in pediatric OS, a multidrug nanomedicine was designed using the alkyl-lysophospholipid edelfosine (EF) co-assembled with squalenoyl–gemcitabine (SQ–Gem) to form nanoassemblies (NAs) of 50 nm. SQ–Gem/EF NAs modified the total Gem pool exposure in the blood stream in comparison with SQ–Gem NAs, which correlated with a better tolerability and a lower toxicity profile after multiple intravenous administrations in mice. For in vivo preclinical assessment in an orthotopic OS tumor model, P1.15 OS cells were intratibially injected in athymic nude mice. SQ–Gem/EF NAs considerably decreased the primary tumor growth kinetics and reduced the number of lung metastases. Our findings support the candidature of this anticancer nanomedicine as a potential pediatric OS therapy.
Open AccessCombinatorial Nanomedicine Made of Squalenoyl-Gemcitabine and Edelfosine for the Treatment of Osteosarcoma
Due to chemoresistance and a high propensity to form lung metastasis, survival rates in pediatric osteosarcoma (OS) are poor. With the aim to improve anticancer activity in pediatric OS, a multidrug nanomedicine was designed using the alkyl-lysophospholipid edelfosine (EF) co-assembled with squalenoyl–gemcitabine (SQ–Gem) to form nanoassemblies (NAs) of 50 nm. SQ–Gem/EF NAs modified the total Gem pool exposure in the blood stream in comparison with SQ–Gem NAs, which correlated with a better tolerability and a lower toxicity profile after multiple intravenous administrations in mice. For in vivo preclinical assessment in an orthotopic OS tumor model, P1.15 OS cells were intratibially injected in athymic nude mice. SQ–Gem/EF NAs considerably decreased the primary tumor growth kinetics and reduced the number of lung metastases. Our findings support the candidature of this anticancer nanomedicine as a potential pediatric OS therapy.